CTI BioPharma Corp. Company Profile (NASDAQ:CTIC)

About CTI BioPharma Corp.

CTI BioPharma Corp. logoCTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (ISTs), such as the ongoing maintenance therapy trial in patients with ovarian cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CTIC
  • CUSIP:
Key Metrics:
  • Previous Close: $4.25
  • 50 Day Moving Average: $4.90
  • 200 Day Moving Average: $1.56
  • 52-Week Range: $3.07 - $7.60
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.57
  • P/E Growth: 0.00
  • Market Cap: $119.00M
  • Outstanding Shares: 28,001,000
  • Beta: 0.96
Profitability:
  • Net Margins: -119.60%
  • Return on Equity: -188.29%
  • Return on Assets: -64.52%
Debt:
  • Debt-to-Equity Ratio: 1.07%
  • Current Ratio: 1.47%
  • Quick Ratio: 1.41%
Additional Links:
Companies Related to CTI BioPharma Corp.:

Analyst Ratings

Consensus Ratings for CTI BioPharma Corp. (NASDAQ:CTIC) (?)
Ratings Breakdown: 1 Hold Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $7.50 (76.47% upside)

Analysts' Ratings History for CTI BioPharma Corp. (NASDAQ:CTIC)
Show:
DateFirmActionRatingPrice TargetDetails
8/29/2016Piper Jaffray CompaniesReiterated RatingNeutral$7.50View Rating Details
2/10/2016Ladenburg Thalmann Financial ServicesDowngradeBuy -> NeutralView Rating Details
2/10/2016WallachBeth CapitalDowngradeHold -> SellView Rating Details
2/8/2016S&P Equity ResearchLower Price Target$4.80 -> $3.90View Rating Details
8/14/2015Roth CapitalReiterated RatingBuy$45.00View Rating Details
6/1/2015Janney Montgomery ScottReiterated RatingBuy -> Fair Value$35.00 -> $19.40View Rating Details
5/10/2015HC WainwrightReiterated RatingBuy$60.00 -> $40.00View Rating Details
(Data available from 2/24/2015 forward)

Earnings

Earnings History for CTI BioPharma Corp. (NASDAQ:CTIC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/17/2017        
5/10/2016Q1($0.04)$0.01ViewN/AView Earnings Details
2/16/2016Q4($0.18)($0.13)ViewN/AView Earnings Details
11/5/2015Q315($0.12)($0.19)$18.89 million$1.00 millionViewListenView Earnings Details
8/6/2015Q215($0.10)($0.19)$12.77 million$1.10 millionViewListenView Earnings Details
5/6/2015Q115($0.14)($0.16)$9.84 million$2.73 millionViewListenView Earnings Details
3/12/2015Q414($0.18)($0.27)$2.48 million$17.80 millionViewListenView Earnings Details
10/29/2014Q3$0.03$0.03ViewListenView Earnings Details
8/4/2014Q2($0.12)($0.19)ViewListenView Earnings Details
4/29/2014Q114($0.17)($0.20)$1.10 million$1.40 millionViewN/AView Earnings Details
3/4/2014Q4($0.16)$0.08$1.26 million$32.90 millionViewListenView Earnings Details
2/28/2013Q4 2012($0.20)($0.20)$1.00 millionViewListenView Earnings Details
11/1/2012Q312($0.38)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for CTI BioPharma Corp. (NASDAQ:CTIC)
Current Year EPS Consensus Estimate: $-1.95 EPS
Next Year EPS Consensus Estimate: $-2.70 EPS

Dividends

Dividend History for CTI BioPharma Corp. (NASDAQ:CTIC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for CTI BioPharma Corp. (NASDAQ:CTIC)
Insider Ownership Percentage: 3.01%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/24/2016James A BiancoCEOSell10,000$0.37$3,700.00View SEC Filing  
5/27/2016James A BiancoCEOSell10,000$0.45$4,500.00View SEC Filing  
4/29/2016James A BiancoCEOSell10,000$0.52$5,200.00View SEC Filing  
3/28/2016James A BiancoCEOSell10,000$0.49$4,900.00View SEC Filing  
3/21/2016James A BiancoCEOSell318,169$0.55$174,992.95View SEC Filing  
3/4/2016Matthew PlunkettEVPSell10,000$0.59$5,900.00View SEC Filing  
2/26/2016Jack W SingerEVPSell15,000$0.63$9,450.00View SEC Filing  
2/26/2016James A BiancoCEOSell10,000$0.63$6,300.00View SEC Filing  
2/16/2016James A BiancoCEOSell100,000$0.42$42,000.00View SEC Filing  
2/4/2016Matthew PlunkettEVPSell10,000$1.15$11,500.00View SEC Filing  
1/29/2016Jack W. SingerEVPSell15,000$1.18$17,700.00View SEC Filing  
1/29/2016James A BiancoCEOSell10,000$1.20$12,000.00View SEC Filing  
1/8/2016Value Fund L P BiotechnologyInsiderBuy1,001,327$1.22$1,221,618.94View SEC Filing  
1/4/2016Matthew PlunkettEVPSell10,000$1.21$12,100.00View SEC Filing  
12/30/2015James A. BiancoCEOSell110,000$1.26$138,600.00View SEC Filing  
12/28/2015James A. BiancoCEOSell10,000$1.29$12,900.00View SEC Filing  
12/18/2015Jack W. SingerEVPSell15,000$1.18$17,700.00View SEC Filing  
12/4/2015Matthew PlunkettEVPSell10,000$1.00$10,000.00View SEC Filing  
11/27/2015Jack W. SingerEVPSell15,000$1.21$18,150.00View SEC Filing  
11/27/2015James A BiancoCEOSell10,000$1.23$12,300.00View SEC Filing  
11/19/2015Louis A. BiancoEVPSell15,000$1.13$16,950.00View SEC Filing  
10/30/2015James A BiancoCEOSell260,000$1.35$351,000.00View SEC Filing  
10/29/2015Louis A. BiancoEVPSell10,000$1.41$14,100.00View SEC Filing  
10/23/2015Jack W. SingerEVPSell15,000$1.62$24,300.00View SEC Filing  
10/22/2015Louis A BiancoEVPSell10,000$1.58$15,800.00View SEC Filing  
10/5/2015Matthew PlunkettEVPSell10,000$1.52$15,200.00View SEC Filing  
9/30/2015Jack W. SingerEVPSell100,000$1.42$142,000.00View SEC Filing  
9/30/2015James A. BiancoCEOSell600,000$1.43$858,000.00View SEC Filing  
9/30/2015Richard L. LoveDirectorSell13,660$1.45$19,807.00View SEC Filing  
9/29/2015Louis A. BiancoEVPSell170,000$1.41$239,700.00View SEC Filing  
9/25/2015Jack W. SingerEVPSell15,000$1.64$24,600.00View SEC Filing  
9/24/2015Matthew PlunkettEVPSell75,869$1.57$119,114.33View SEC Filing  
9/4/2015Matthew PlunkettEVPSell10,000$1.54$15,400.00View SEC Filing  
8/28/2015Jack W. SingerEVPSell15,000$1.58$23,700.00View SEC Filing  
7/24/2015Jack W SingerEVPSell15,000$1.91$28,650.00View SEC Filing  
7/23/2015Louis A BiancoEVPSell10,000$1.91$19,100.00View SEC Filing  
7/6/2015Matthew PlunkettEVPSell10,000$1.95$19,500.00View SEC Filing  
6/26/2015Jack W SingerEVPSell15,000$2.07$31,050.00View SEC Filing  
6/25/2015Louis A BiancoEVPSell10,000$2.18$21,800.00View SEC Filing  
6/4/2015Matthew PlunkettEVPSell10,000$2.06$20,600.00View SEC Filing  
5/22/2015Jack W SingerEVPSell15,000$1.74$26,100.00View SEC Filing  
5/21/2015Louis A BiancoEVPSell10,000$1.80$18,000.00View SEC Filing  
5/4/2015Matthew PlunkettEVPSell10,000$1.86$18,600.00View SEC Filing  
4/24/2015Jack W SingerEVPSell15,000$1.96$29,400.00View SEC Filing  
4/23/2015Louis A BiancoEVPSell10,000$1.93$19,300.00View SEC Filing  
4/6/2015Matthew PlunkettEVPSell16,569$1.88$31,149.72View SEC Filing  
3/23/2015James A BiancoCEOSell175,199$1.95$341,638.05View SEC Filing  
3/23/2015Matthew PlunkettEVPSell59,130$1.96$115,894.80View SEC Filing  
3/20/2015Louis A BiancoEVPSell63,000$1.94$122,220.00View SEC Filing  
2/27/2015Jack W SingerEVPSell15,000$2.35$35,250.00View SEC Filing  
2/5/2015Louis A BiancoEVPSell10,000$2.22$22,200.00View SEC Filing  
2/4/2015Matthew PlunkettEVPSell12,000$2.22$26,640.00View SEC Filing  
1/8/2015Louis A BiancoEVPSell10,000$2.32$23,200.00View SEC Filing  
1/5/2015Matthew PlunkettEVPSell12,000$2.36$28,320.00View SEC Filing  
12/19/2014James A BiancoCEOSell40,000$2.44$97,600.00View SEC Filing  
12/4/2014Louis A BiancoEVPSell10,000$2.25$22,500.00View SEC Filing  
11/6/2014Louis A BiancoEVPSell10,000$2.37$23,700.00View SEC Filing  
10/6/2014Matthew PlunkettEVPSell12,000$2.39$28,680.00View SEC Filing  
9/23/2014Matthew PlunkettEVPSell103,635$2.56$265,305.60View SEC Filing  
9/22/2014James A BiancoCEOSell307,068$2.53$776,882.04View SEC Filing  
9/22/2014Matthew PlunkettEVPSell51,817$2.58$133,687.86View SEC Filing  
9/19/2014Louis A BiancoEVPSell145,000$2.59$375,550.00View SEC Filing  
9/4/2014Matthew PlunkettEVPSell27,301$2.48$67,706.48View SEC Filing  
8/15/2014James A BiancoCEOSell40,000$2.54$101,600.00View SEC Filing  
8/4/2014Matthew PlunkettEVPSell12,000$2.48$29,760.00View SEC Filing  
7/10/2014Louis A BiancoEVPSell10,000$2.73$27,300.00View SEC Filing  
7/7/2014Matthew PlunkettEVPSell12,000$2.89$34,680.00View SEC Filing  
6/27/2014James A BiancoCEOSell50,000$2.84$142,000.00View SEC Filing  
6/5/2014Louis A BiancoEVPSell10,000$2.97$29,700.00View SEC Filing  
5/1/2014Louis BiancoEVPSell10,000$2.91$29,100.00View SEC Filing  
3/28/2014Vartan GregorianDirectorSell82,000$3.41$279,620.00View SEC Filing  
3/25/2014Phillip Phd NudelmanDirectorSell100,000$3.56$356,000.00View SEC Filing  
3/24/2014Jack SingerEVPSell60,000$3.47$208,200.00View SEC Filing  
3/21/2014James BiancoCEOSell395,000$3.83$1,512,850.00View SEC Filing  
3/21/2014Matthew PlunkettEVPSell170,000$3.73$634,100.00View SEC Filing  
3/7/2014Fred TellingDirectorSell72,095$3.75$270,356.25View SEC Filing  
9/23/2013James A BiancoCEOSell130,551$1.50$195,826.50View SEC Filing  
8/30/2013James A BiancoCEOSell25,925$1.08$27,999.00View SEC Filing  
8/9/2013James A BiancoCEOSell40,000$1.07$42,800.00View SEC Filing  
8/7/2013Mary Oneil MundingerDirectorSell125,000$1.06$132,500.00View SEC Filing  
8/6/2013Phillip M Phd NudelmanDirectorSell50,000$1.09$54,500.00View SEC Filing  
7/26/2013James A BiancoCEOSell25,688$1.09$27,999.92View SEC Filing  
6/28/2013James A BiancoCEOSell26,053$1.08$28,137.24View SEC Filing  
6/5/2013Jack W SingerEVPSell10,000$1.26$12,600.00View SEC Filing  
5/31/2013James A BiancoCEOSell28,000$1.22$34,160.00View SEC Filing  
5/31/2013Louis A BiancoEVPSell33,712$1.24$41,802.88View SEC Filing  
5/30/2013Fred TellingDirectorSell64,798$1.24$80,349.52View SEC Filing  
5/24/2013Richard L LoveDirectorSell23,000$1.21$27,830.00View SEC Filing  
5/10/2013James A BiancoCEOSell25,000$1.16$29,000.00View SEC Filing  
5/9/2013Louis A BiancoEVPSell50,000$1.15$57,500.00View SEC Filing  
3/11/2013Jack W SingerEVPSell13,000$1.28$16,640.00View SEC Filing  
8/10/2012James A BiancoCEOSell10,000$0.42$4,200.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for CTI BioPharma Corp. (NASDAQ:CTIC)
DateHeadline
News IconAnalysts Peeling Back The Layers on CTI BioPharma Corp. (NASDAQ:CTIC): Consensus Take - Winfield Review (NASDAQ:CTIC)
winfieldreview.com - February 23 at 9:32 PM
News IconAnalysts Are Circling CTI BioPharma Corp. (NASDAQ:CTIC): Where Do Research Brokers See It Going? - Winfield Review (NASDAQ:CTIC)
winfieldreview.com - February 23 at 2:49 AM
News IconChecking Indicator Levels for CTi Biopharma Corp (CTIC) - Rives Journal (NASDAQ:CTIC)
rivesjournal.com - February 23 at 2:49 AM
prnewswire.com logoCTI BioPharma to Report Fourth Quarter and Full Year 2016 Financial Results on March 2, 2017 - PR Newswire (press release) (NASDAQ:CTIC)
www.prnewswire.com - February 23 at 2:49 AM
finance.yahoo.com logoCTI BioPharma to Report Fourth Quarter and Full Year 2016 Financial Results on March 2, 2017 (NASDAQ:CTIC)
finance.yahoo.com - February 23 at 2:49 AM
News IconLooking at the Levels on Shares of CTI BioPharma Corp. (NASDAQ:CTIC) - SKV News (NASDAQ:CTIC)
skvnews.com - February 17 at 3:36 PM
News IconPulling Back The Curtain on CTI BioPharma Corp. (NASDAQ:CTIC): Analysts & Wall Street Chime In - Winfield Review (NASDAQ:CTIC)
winfieldreview.com - February 17 at 8:22 AM
seekingalpha.com logoCTI BioPharma (CTIC) Presents At 19th Annual BIO CEO & Investor Conference - Slideshow (NASDAQ:CTIC)
seekingalpha.com - February 16 at 1:29 PM
News IconSetting the Table For Earnings, Stock In Focus: CTI BioPharma Corp. (NASDAQ:CTIC) - Aiken Advocate (NASDAQ:CTIC)
aikenadvocate.com - February 15 at 1:26 AM
News IconAnalysts Weigh in on CTI BioPharma Corp. (NASDAQ:CTIC), Consensus Targets in Focus - Rockville Register (NASDAQ:CTIC)
rockvilleregister.com - February 14 at 8:23 PM
marketexclusive.com logoCTI BIOPHARMA CORP. (NASDAQ:CTIC) Files An 8-K Other Events (NASDAQ:CTIC)
marketexclusive.com - February 12 at 4:34 PM
finance.yahoo.com logoCTI BioPharma to Present at the BIO CEO & Investor Conference (NASDAQ:CTIC)
finance.yahoo.com - February 8 at 3:43 AM
4-traders.com logoCTI BIOPHARMA CORP : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) (NASDAQ:CTIC)
www.4-traders.com - February 1 at 3:30 AM
News IconWatching the Levels for CTI BioPharma Corp. (NASDAQ:CTIC) - The Tribune (NASDAQ:CTIC)
lakecitytribune.com - January 31 at 5:04 PM
News IconAnalysts Take: CTI BioPharma Corp. (NASDAQ:CTIC) Projected Earnings & Price Targets - Aiken Advocate (NASDAQ:CTIC)
aikenadvocate.com - January 31 at 5:04 PM
News IconEarnings Snapshot & Analysts Target Update on CTI BioPharma Corp. (NASDAQ:CTIC)? - Wall Street Beacon (NASDAQ:CTIC)
wsbeacon.com - January 31 at 5:04 PM
News IconCTI BioPharma Corp. (NASDAQ:CTIC) Stock Alert: Price Target in Focus - Aiken Advocate (NASDAQ:CTIC)
aikenadvocate.com - January 31 at 5:04 PM
News IconIs There Inherent Value in CTI BioPharma Corp. (NASDAQ:CTIC)? Analysts Delve Into The Stock - Wall Street Beacon (NASDAQ:CTIC)
wsbeacon.com - January 28 at 4:03 AM
News IconAnalysts Peering Into Their Crystal Balls, What's the Sentiment on CTI BioPharma Corp. (NASDAQ:CTIC) - Wall Street Beacon (NASDAQ:CTIC)
wsbeacon.com - January 26 at 5:42 PM
News IconAnalysts Take Aim At This Stock's Earnings Estimates: CTI BioPharma Corp. (NASDAQ:CTIC) - Aiken Advocate (NASDAQ:CTIC)
aikenadvocate.com - January 25 at 3:16 AM
prnewswire.com logoCTI BioPharma Appoints Leading BioPharma Executive Michael ... - PR Newswire (press release) (NASDAQ:CTIC)
www.prnewswire.com - January 25 at 3:16 AM
News IconPeeling Back The Layers on CTI BioPharma Corp. (NASDAQ:CTIC): Sell-Side Weighs In - Wall Street Beacon (NASDAQ:CTIC)
wsbeacon.com - January 25 at 3:16 AM
finance.yahoo.com logoCTI BioPharma Appoints Leading BioPharma Executive Michael Metzger To Board Of Directors (NASDAQ:CTIC)
finance.yahoo.com - January 24 at 5:11 PM
biz.yahoo.com logoCTI BIOPHARMA CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits (NASDAQ:CTIC)
biz.yahoo.com - January 24 at 5:11 PM
News IconBrokerage Analyst Weighing in on CTI BioPharma Corp. (NASDAQ:CTIC) - Aiken Advocate (NASDAQ:CTIC)
aikenadvocate.com - January 22 at 9:35 PM
News IconBrokerage Firm Target Update for CTI BioPharma Corp. (NASDAQ:CTIC) - Aiken Advocate (NASDAQ:CTIC)
aikenadvocate.com - January 22 at 2:38 AM
marketexclusive.com logoCTI BIOPHARMA CORP. (NASDAQ:CTIC) Files An 8-K Other Events - Market Exclusive (NASDAQ:CTIC)
marketexclusive.com - January 22 at 2:38 AM
News IconCan CTI BioPharma Corp. (NASDAQ:CTIC) Hit 7.5? - Aiken Advocate (NASDAQ:CTIC)
aikenadvocate.com - January 21 at 3:47 AM
4-traders.com logoCTI BioPharma : Announces Removal Of Full Clinical Hold On Pacritinib (NASDAQ:CTIC)
www.4-traders.com - January 20 at 10:44 PM
finance.yahoo.com logo6:11 pm CTI BioPharma regained compliance with Nasdaq Listing Rule for minimum bid price; matter is now closed (NASDAQ:CTIC)
finance.yahoo.com - January 20 at 10:44 PM
News IconAnalysts Pull Back the Curtain on CTI BioPharma Corp. (NASDAQ:CTIC): Consensus Update - Wall Street Beacon (NASDAQ:CTIC)
wsbeacon.com - January 20 at 5:44 PM
biz.yahoo.com logoCTI BIOPHARMA CORP Files SEC form 8-K, Other Events (NASDAQ:CTIC)
biz.yahoo.com - January 20 at 5:44 PM
4-traders.com logoCTI BioPharma : Announces Progress Of Lead Programs And Strategic Objectives For 2017 (NASDAQ:CTIC)
www.4-traders.com - January 19 at 5:50 PM
News IconDid Buying Come Too Strong Too Quickly? Shares Reach Overbought Range: CTI BioPharma Corp. (NASDAQ:CTIC) - Wall Street Beacon (NASDAQ:CTIC)
wsbeacon.com - January 19 at 2:58 AM
News IconAre Analysts Pounding the Table on CTI BioPharma Corp. (NASDAQ:CTIC) In 2017? - Wall Street Beacon (NASDAQ:CTIC)
wsbeacon.com - January 19 at 2:58 AM
News IconStock Backsliding Ahead of the Bell, Gapping Down: CTI BioPharma Corp. (NASDAQ:CTIC) - Aiken Advocate (NASDAQ:CTIC)
aikenadvocate.com - January 18 at 9:57 PM
News IconDid Buying Come Too Strong Too Quickly? Shares Reach ... - Wall Street Beacon (NASDAQ:CTIC)
wsbeacon.com - January 18 at 9:57 PM
News IconPumping the Brakes as Stock Dragged Lower Mid-Session: CTI BioPharma Corp. (NASDAQ:CTIC) - Wall Street Beacon (NASDAQ:CTIC)
wsbeacon.com - January 18 at 9:57 PM
News IconEarnings Fever Sweeping In, What Are Analysts Expecting From CTI BioPharma Corp. (NASDAQ:CTIC)? - Wall Street Beacon (NASDAQ:CTIC)
wsbeacon.com - January 17 at 10:27 PM
News IconChartists Take Note of Relative Strength Index of CTI BioPharma Corp. (NASDAQ:CTIC) - Wall Street Beacon (NASDAQ:CTIC)
wsbeacon.com - January 17 at 10:27 PM
News IconWall Street and Armchair Analysts Weigh in on CTI BioPharma Corp. (NASDAQ:CTIC) Heading Into The New Year - Wall Street Beacon (NASDAQ:CTIC)
wsbeacon.com - January 17 at 8:39 AM
News IconCTI BioPharma Corp CTIC Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:CTIC)
www.bioportfolio.com - January 16 at 4:35 PM
News IconInvestor Alert: Price Target Predictions for CTI BioPharma Corp. (NASDAQ:CTIC) - Aiken Advocate (NASDAQ:CTIC)
aikenadvocate.com - January 16 at 10:21 AM
News IconMarkets End Mostly Higher, How Did This Stock Fare: CTI BioPharma Corp. (NASDAQ:CTIC) - Wall Street Beacon (NASDAQ:CTIC)
wsbeacon.com - January 14 at 4:38 PM
News IconTechnicals in Focus for CTI BioPharma Corp. (CTIC) - The USA Commerce (NASDAQ:CTIC)
theusacommerce.com - January 14 at 4:38 PM
News IconWhat's Are Analysts Expecting of CTI BioPharma Corp. (NASDAQ:CTIC) In 2017? - Wall Street Beacon (NASDAQ:CTIC)
wsbeacon.com - January 12 at 3:03 AM
nasdaq.com logoCTI BioPharma Announces 2017 Key Objectives - Quick Facts ... - Nasdaq (NASDAQ:CTIC)
www.nasdaq.com - January 11 at 5:00 PM
News IconStock Reaching Most Volatile List Today: CTI BioPharma Corp. (NASDAQ:CTIC) - Wall Street Beacon (NASDAQ:CTIC)
wsbeacon.com - January 11 at 5:00 PM
finance.yahoo.com logoLatest Reports on Recent Market Movers: 3D Systems and CTI BioPharma (NASDAQ:CTIC)
finance.yahoo.com - January 10 at 5:29 PM
marketexclusive.com logoCTI BIOPHARMA CORP. (NASDAQ:CTIC) Files An 8-K Results of Operations and Financial Condition - Market Exclusive (NASDAQ:CTIC)
marketexclusive.com - January 9 at 9:12 PM

Social

What is CTI BioPharma Corp.'s stock symbol?

CTI BioPharma Corp. trades on the NASDAQ under the ticker symbol "CTIC."

When did CTI BioPharma Corp.'s stock split? How did CTI BioPharma Corp.'s stock split work?

CTI BioPharma Corp.'s stock reverse split on the morning of Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 30th 2016. An investor that had 100 shares of CTI BioPharma Corp. stock prior to the reverse split would have 10 shares after the split.

Where is CTI BioPharma Corp.'s stock going? Where will CTI BioPharma Corp.'s stock price be in 2017?

1 brokers have issued 12-month price targets for CTI BioPharma Corp.'s shares. Their predictions range from $7.50 to $7.50. On average, they expect CTI BioPharma Corp.'s stock price to reach $7.50 in the next twelve months.

When will CTI BioPharma Corp. announce their earnings?

CTI BioPharma Corp. is scheduled to release their next quarterly earnings announcement on Friday, February, 17th 2017.

Who owns CTI BioPharma Corp. stock?

CTI BioPharma Corp.'s stock is owned by many different of retail and institutional investors. Top institutional shareholders include Stonepine Capital Management LLC (9.35%), Renaissance Technologies LLC (6.22%), FMR LLC (3.40%), United Capital Financial Advisers LLC (1.88%) and Commerzbank Aktiengesellschaft FI (1.27%). Company insiders that own CTI BioPharma Corp. stock include Jack W Singer, James A Bianco, Louis A Bianco, Matthew Plunkett, Richard L Love and Value Fund L P Biotechnology.

Who sold CTI BioPharma Corp. stock? Who is selling CTI BioPharma Corp. stock?

CTI BioPharma Corp.'s stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Renaissance Technologies LLC and Commerzbank Aktiengesellschaft FI. Company insiders that have sold CTI BioPharma Corp. stock in the last year include Jack W Singer, James A Bianco and Matthew Plunkett.

Who bought CTI BioPharma Corp. stock? Who is buying CTI BioPharma Corp. stock?

CTI BioPharma Corp.'s stock was bought by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC.

How do I buy CTI BioPharma Corp. stock?

Shares of CTI BioPharma Corp. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of CTI BioPharma Corp. stock cost?

One share of CTI BioPharma Corp. stock can currently be purchased for approximately $4.25.

CTI BioPharma Corp. (NASDAQ:CTIC) Chart for Friday, February, 24, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for CTI BioPharma Corp. (NASDAQ:CTIC)

Earnings History Chart

Earnings by Quarter for CTI BioPharma Corp. (NASDAQ:CTIC)

Dividend History Chart

Dividend Payments by Quarter for CTI BioPharma Corp. (NASDAQ:CTIC)

Last Updated on 2/24/2017 by MarketBeat.com Staff